10/2/2023 | PV | Amicus Therapeutics sells 2,467,104 shares via private placement; $400 million loan arranged
|
7/17/2020 | BK | Amicus Therapeutics arranges $400 million credit facility with Hayfin
|
7/17/2020 | PV | New Issue: Amicus Therapeutics arranges $400 million credit facility with Hayfin
|
3/13/2019 | CVLM | Amicus agrees to swap $34.7 million of 3% convertibles for stock
|
1/24/2019 | CVLM | Amicus agrees to swap $152.1 million of 3% convertibles for stock
|
9/20/2018 | BKBWHY | Amicus gets $150 million debt facility to buy gene therapy programs
|
9/20/2018 | PV | Amicus gets $150 million five-year loan with BioPharma for asset buy
|
12/21/2016 | CV | Amicus greenshoe exercised, lifts 3% convertibles to $250 million
|
12/16/2016 | CV | Market Commentary: New deals in focus; upsized Finisar moves higher in active trade; Amicus slips below par
|
12/16/2016 | CV | Market Commentary: Morning Commentary: New, upsized Finisar moves higher in active trade; new Amicus below par
|
12/15/2016 | CV | New Issue: Amicus Therapeutics prices $225 million seven-year convertibles to yield 3%, up 27.5%
|
12/15/2016 | CV | Market Commentary: Calendar builds with deals from NantHealth, Amicus, Finisar; notes from Aegean, WWE fizzle
|
12/15/2016 | CV | Market Commentary: Morning Commentary: NantHealth, Amicus Therapeutics in the market; Aegean’s new issue below par
|
12/14/2016 | CV | Market Commentary: Aegean deal comes upsized, in mid-range of talk; Aerojet falls below par; Amicus on tap
|
12/14/2016 | CV | Amicus Therapeutics to sell $225 million seven-year convertible notes at 2.75%-3.25%, up 25%-30%
|
7/1/2016 | PP | Amicus settles $80 million 3.875% notes sale with $30 million tranche
|
2/22/2016 | PP | Amicus wraps $50 million of $75 million 3.875% promissory notes sale
|
10/1/2015 | PP | Amicus Therapeutics seals $50 million unsecured promissory notes sale
|
3/4/2014 | PP | Amicus Therapeutics arranges $40 million at-the-market sales agreement
|
11/20/2013 | PP | Amicus Therapeutics arranges $3 million private placement of its stock
|
12/6/2012 | CVHYPF | Amicus Therapeutics files $145 million stock, debt, preferreds shelf
|
3/2/2012 | PP | Amicus Therapeutics prices $57 million public sale of common shares
|
3/1/2012 | PP | Amicus Therapeutics plans to price public offering of common shares
|
11/2/2010 | PP | Amicus Therapeutics prices $31.31 million private placement of stock
|
2/25/2010 | PP | New Issue: Amicus orchestrates $18.51 million registered direct offering of stock
|
4/3/2009 | CVHY | Amicus Therapeutics files $100 million shelf with SEC
|
8/7/2007 | SS | Amicus investor buys more shares of company's stock
|
9/14/2006 | BT | Amicus raises $60 million in series D round
|
8/2/2006 | BT | Amicus Therapeutics pulls $86.25 million IPO
|
5/17/2006 | BT | Amicus Therapeutics files for $86.25 million IPO
|
9/8/2005 | BT | Amicus Therapeutics raises $55 million in series C financing
|